Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
2
40%
Ph phase_3
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

completed480%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472
completedphase_3

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

NCT07030595
completedphase_1

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

NCT06100627
completedphase_2

Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation

NCT02095626
completedphase_2

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

NCT01627613

Clinical Trials (5)

Showing 5 of 5 trials
NCT06933472Phase 3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Recruiting
NCT07030595Phase 3

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

Completed
NCT06100627Phase 1

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

Completed
NCT02095626Phase 2

Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation

Completed
NCT01627613Phase 2

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5